Overview

  • Product name
    Anti-Cyclin D1 antibody [SP4]
    See all Cyclin D1 primary antibodies
  • Description
    Rabbit monoclonal [SP4] to Cyclin D1
  • Tested applications
    Suitable for: WB, IHC-P, ICC, IPmore details
    Unsuitable for: Flow Cyt
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide from the C-terminal region of Human Cyclin D1.

  • Positive control
    • MCF7 cell lysate; Human mantle cell lymphoma tissue. ICC/IF: HAP1 cells (HAP1-CCND1 knockout cells used as negative cell line)
  • General notes

    A trial size is available to purchase for this antibody.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

Properties

Applications

Our Abpromise guarantee covers the use of ab137875 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Predicted molecular weight: 34 kDa.
IHC-P 1/100.
ICC 1/250.
IP 1/20.
  • Application notes
    Is unsuitable for Flow Cyt.
  • Target

    • Function
      Essential for the control of the cell cycle at the G1/S (start) transition.
    • Involvement in disease
      Note=A chromosomal aberration involving CCND1 may be a cause of B-lymphocytic malignancy, particularly mantle-cell lymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulin gene regions. Activation of CCND1 may be oncogenic by directly altering progression through the cell cycle.
      Note=A chromosomal aberration involving CCND1 may be a cause of parathyroid adenomas. Translocation t(11;11)(q13;p15) with the parathyroid hormone (PTH) enhancer.
      Defects in CCND1 are a cause of multiple myeloma (MM) [MIM:254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving CCND1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus.
    • Sequence similarities
      Belongs to the cyclin family. Cyclin D subfamily.
    • Post-translational
      modifications
      Phosphorylation at Thr-286 by MAP kinases is required for ubiquitination and degradation following DNA damage. It probably plays an essential role for recognition by the FBXO31 component of SCF (SKP1-cullin-F-box) protein ligase complex.
      Ubiquitinated, primarily as 'Lys-48'-linked polyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-box protein) ubiquitin-protein ligase complex containing FBXO4 and CRYAB (By similarity). Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. Ubiquitination leads to its degradation and G1 arrest. Deubiquitinated by USP2; leading to stabilize it.
    • Cellular localization
      Nucleus.
    • Information by UniProt
    • Database links
    • Alternative names
      • AI327039 antibody
      • B cell CLL/lymphoma 1 antibody
      • B cell leukemia 1 antibody
      • B cell lymphoma 1 protein antibody
      • B-cell lymphoma 1 protein antibody
      • BCL 1 antibody
      • BCL-1 antibody
      • BCL-1 oncogene antibody
      • BCL1 antibody
      • BCL1 oncogene antibody
      • ccnd1 antibody
      • CCND1/FSTL3 fusion gene, included antibody
      • CCND1/IGHG1 fusion gene, included antibody
      • CCND1/IGLC1 fusion gene, included antibody
      • CCND1/PTH fusion gene, included antibody
      • CCND1_HUMAN antibody
      • cD1 antibody
      • Cyl 1 antibody
      • D11S287E antibody
      • G1/S specific cyclin D1 antibody
      • G1/S-specific cyclin-D1 antibody
      • Parathyroid adenomatosis 1 antibody
      • PRAD1 antibody
      • PRAD1 oncogene antibody
      • U21B31 antibody
      see all

    Images



    • Predicted band size : 34 kDa

      Lanes:
      Lane 1: Empty
      Lane 2: Wild type HAP1 whole cell lysate (20 µg)
      Lane 3: Cyclin D1 knockout HAP1 whole cell lysate (20 µg)
      Lane 4: A431 whole cell lysate (20 µg) 

      Lanes 1 - 4: Merged signal (red and green). Green - ab137875 observed at 35 kDa. Red - loading control, ab18058, observed at 130 kDa.

      ab137875 was shown to specifically react with HAP1 when HAP1 knockout samples were used. Wild-type and HAP1 knockout samples were subjected to SDS-PAGE. Ab137875 and ab18058 (Mouse anti Vinculin loading control) were incubated overnight at 4°C at 1000 dilution and 1/10000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.

    • ab137875 staining Cyclin D1 in wild-type HAP1 cells (top panel) and CCND1 knockout HAP1 cells (bottom panel). The cells were fixed with 100% methanol (5min), permeabilized with 0.1% Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1% PBS-Tween for 1h. The cells were then incubated with ab137875 at 1/250 dilution and ab195889 at 1/250 dilution (shown in pseudocolour red) overnight at +4°C, followed by a further incubation at room temperature for 1h with a goat secondary antibody to Rabbit IgG (Alexa Fluor® 488) (ab150081) at 2 μg/ml (shown in green). Nuclear DNA was labelled in blue with DAPI.

      Image was taken with a confocal microscope (Leica-Microsystems, TCS SP8).

    • Immunohistochemical analysis of paraffin-embedded Human mantle cell lymphoma tissue labelling Cyclin D1 with ab137875 at 1/100.
    • All lanes : Anti-Cyclin D1 antibody [SP4] (ab137875) at 1/5000 dilution

      Lane 1 : Human osteosarcoma whole cell lysate - control, non-targeting siRNA
      Lane 2 : Human osteosarcoma whole cell lysate - siRNA for Cyclin D1

      Lysates/proteins at 20 µg per lane.

      Secondary
      HRP-conjugated goat anti-rabbit IgG polyclonal at 1/2000 dilution
      Developed using the ECL technique

      Performed under reducing conditions.

      Predicted band size : 34 kDa
      Observed band size : 34 kDa


      Exposure time : 2 minutes

      This image is courtesy of an Abreview submitted by Sonia Rocha

      See Abreview

    • Immunohistochemical analysis of Human bladder tumour tissue, staining Cyclin D1 with ab137875.

      Antigen retrieval was performed by heat mediation in citrate buffer (pH 6), before being incubated with primary antibody (1/100). Staining was detected using DAB.
    • Anti-Cyclin D1 antibody [SP4] (ab137875) at 1/5000 dilution + MCF7 cell lysate at 10 µg

      Secondary
      Goat anti-rabbit HRP at 1/2000 dilution

      Predicted band size : 34 kDa

    References

    This product has been referenced in:
    • Jin Y  et al. Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer. Oncotarget 8:26090-26099 (2017). Read more (PubMed: 28212533) »
    • Lu C  et al. MicroRNA-320a downregulation mediates human liver cancer cell proliferation through the Wnt/ß-catenin signaling pathway. Oncol Lett 13:573-578 (2017). Read more (PubMed: 28356931) »

    See all 10 Publications for this product

    Customer reviews and Q&As

    Filter by Application

    Filter by Species

    Filter by Ratings

    Application
    Western blot
    Loading amount
    20 µg
    Gel Running Conditions
    Reduced Denaturing (10%)
    Sample
    Human Cell lysate - whole cell (osteosarcoma cells)
    Specification
    osteosarcoma cells
    Treatment
    lane 1 control, lane 2 siRNA for Cyclin D1, 48h
    Blocking step
    Milk as blocking agent for 10 minute(s) · Concentration: 10% · Temperature: 21°C
    Username

    Dr. Sonia Rocha

    Verified customer

    Submitted Sep 26 2014

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up